Interv Akut Kardiol. 2009;8(4):204-207

Rosuvastatin

MUDr. Michal Vrablík Ph.D

III. interní klinika VFN a 1. LF UK, Praha

Rosuvastatin has been introduced into the Czech market only recently. It possesses beneficial pharmacological properties and the greatest

lipid-lowering potency of all available statins. Clinical trials with rosuvastatin using atherosclerosis paging (ASTEROID, METEOR)

have shown its ability of slowing atherosclerosis progression and even inducing regression of atherosclerotic vascular lesions. In the

CORONA and AURORA studies, adding rosuvastatin to medication of heart and kidney failure patients was not associated with any

benefits. On the contrary, in the JUPITER trial, which included patients with low LDL-cholesterol levels at baseline rosuvastatin significantly

reduced risk of cardiovascular events and, moreover, the all cause mortality by 20 %. Although rosuvastatin lacks data on

some patient populations (e. g. secondary prevention, acute coronary syndrome patients), it can be expected to become widely used

in high-risk patients.

Keywords: rosuvastatin, cardiovascular disease, prevention, cholesterol, dyslipidemia, cardiovascular risk.

Published: September 1, 2009  Show citation